Synergen applies to market Antril in Europe

Synergen Inc. submitted an application to the Committee for Proprietary Medicinal Products for European marketing approval of Antril interleukin-1 receptor antagonist to treat severe sepsis.

The submission is based on the results of SYGN's Phase III trial, which were presented last March. Those results suggested that